Cargando…

Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation

PURPOSE: To develop a model to predict recurrence for patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) treated with intravesical chemotherapy which can be challenging because of the heterogeneous characteristics of these patients. METHODS: Data from three Dutch trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Lammers, Rianne J. M., Hendriks, Jan C. M., Rodriguez Faba, O. Rodriguez Faba, Witjes, Wim P. J., Palou, Joan, Witjes, J. Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729802/
https://www.ncbi.nlm.nih.gov/pubmed/26025189
http://dx.doi.org/10.1007/s00345-015-1598-0
_version_ 1782412297085386752
author Lammers, Rianne J. M.
Hendriks, Jan C. M.
Rodriguez Faba, O. Rodriguez Faba
Witjes, Wim P. J.
Palou, Joan
Witjes, J. Alfred
author_facet Lammers, Rianne J. M.
Hendriks, Jan C. M.
Rodriguez Faba, O. Rodriguez Faba
Witjes, Wim P. J.
Palou, Joan
Witjes, J. Alfred
author_sort Lammers, Rianne J. M.
collection PubMed
description PURPOSE: To develop a model to predict recurrence for patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) treated with intravesical chemotherapy which can be challenging because of the heterogeneous characteristics of these patients. METHODS: Data from three Dutch trials were combined. Patients treated with intravesical chemotherapy with characteristics according to the IR definition of the EAU guideline 2013 were included. Uni- and multivariable Cox regression with selection methods were used to identify predictors of recurrence at 1, 2, and 5 years. An easy-readable table for recurrence probabilities was developed. An external validation was done using data from Spanish patients. RESULTS: A total of 724 patients were available for analyses, of which 305 were primary patients. Recurrences occurred in 413 patients (57 %). History of recurrences, history of intravesical treatment, grade 2, multiple tumors, and adjuvant treatment with epirubicin were relevant predictors for recurrence-free survival with hazard ratios of 1.48, 1.38, 1.22, 1.56, and 1.27, respectively. A table for recurrence probabilities was developed using these five predictors. Based on the probability of recurrence, three risk groups were identified. Patients in each of the separate risk groups should be scheduled for less or more aggressive treatment. The model showed sufficient discrimination and good predictive accuracy. External validation showed good validity. CONCLUSION: In our model, we identified five relevant predictors for recurrence-free survival in IR-NMIBC patients treated with intravesical chemotherapy. These recurrence predictors allow the urologists to stratify patients in risk groups for recurrence that could help in deciding for an individualized treatment approach. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00345-015-1598-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4729802
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-47298022016-02-04 Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation Lammers, Rianne J. M. Hendriks, Jan C. M. Rodriguez Faba, O. Rodriguez Faba Witjes, Wim P. J. Palou, Joan Witjes, J. Alfred World J Urol Original Article PURPOSE: To develop a model to predict recurrence for patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) treated with intravesical chemotherapy which can be challenging because of the heterogeneous characteristics of these patients. METHODS: Data from three Dutch trials were combined. Patients treated with intravesical chemotherapy with characteristics according to the IR definition of the EAU guideline 2013 were included. Uni- and multivariable Cox regression with selection methods were used to identify predictors of recurrence at 1, 2, and 5 years. An easy-readable table for recurrence probabilities was developed. An external validation was done using data from Spanish patients. RESULTS: A total of 724 patients were available for analyses, of which 305 were primary patients. Recurrences occurred in 413 patients (57 %). History of recurrences, history of intravesical treatment, grade 2, multiple tumors, and adjuvant treatment with epirubicin were relevant predictors for recurrence-free survival with hazard ratios of 1.48, 1.38, 1.22, 1.56, and 1.27, respectively. A table for recurrence probabilities was developed using these five predictors. Based on the probability of recurrence, three risk groups were identified. Patients in each of the separate risk groups should be scheduled for less or more aggressive treatment. The model showed sufficient discrimination and good predictive accuracy. External validation showed good validity. CONCLUSION: In our model, we identified five relevant predictors for recurrence-free survival in IR-NMIBC patients treated with intravesical chemotherapy. These recurrence predictors allow the urologists to stratify patients in risk groups for recurrence that could help in deciding for an individualized treatment approach. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00345-015-1598-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-05-30 2016 /pmc/articles/PMC4729802/ /pubmed/26025189 http://dx.doi.org/10.1007/s00345-015-1598-0 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Lammers, Rianne J. M.
Hendriks, Jan C. M.
Rodriguez Faba, O. Rodriguez Faba
Witjes, Wim P. J.
Palou, Joan
Witjes, J. Alfred
Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
title Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
title_full Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
title_fullStr Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
title_full_unstemmed Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
title_short Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
title_sort prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729802/
https://www.ncbi.nlm.nih.gov/pubmed/26025189
http://dx.doi.org/10.1007/s00345-015-1598-0
work_keys_str_mv AT lammersriannejm predictionmodelforrecurrenceprobabilitiesafterintravesicalchemotherapyinpatientswithintermediaterisknonmuscleinvasivebladdercancerincludingexternalvalidation
AT hendriksjancm predictionmodelforrecurrenceprobabilitiesafterintravesicalchemotherapyinpatientswithintermediaterisknonmuscleinvasivebladdercancerincludingexternalvalidation
AT rodriguezfabaorodriguezfaba predictionmodelforrecurrenceprobabilitiesafterintravesicalchemotherapyinpatientswithintermediaterisknonmuscleinvasivebladdercancerincludingexternalvalidation
AT witjeswimpj predictionmodelforrecurrenceprobabilitiesafterintravesicalchemotherapyinpatientswithintermediaterisknonmuscleinvasivebladdercancerincludingexternalvalidation
AT paloujoan predictionmodelforrecurrenceprobabilitiesafterintravesicalchemotherapyinpatientswithintermediaterisknonmuscleinvasivebladdercancerincludingexternalvalidation
AT witjesjalfred predictionmodelforrecurrenceprobabilitiesafterintravesicalchemotherapyinpatientswithintermediaterisknonmuscleinvasivebladdercancerincludingexternalvalidation